Quarterly report pursuant to Section 13 or 15(d)

Revenue - (Details)

v3.20.2
Revenue - (Details) - USD ($)
3 Months Ended 9 Months Ended 16 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Apr. 30, 2021
Disaggregation of Revenue [Line Items]          
Total revenue $ 1,110,794 $ 2,201,232 $ 5,202,423 $ 6,169,543  
Product revenue, net          
Disaggregation of Revenue [Line Items]          
Total revenue $ 1,110,794 $ 2,101,232 $ 5,202,423 $ 6,069,543  
Millipred | Forecast | Teva          
Disaggregation of Revenue [Line Items]          
Semi-annual license payment         $ 75,000
Customer Concentration Risk | Sales Revenue | Major Customer Number One          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage 40.00%   43.00%    
Customer Concentration Risk | Sales Revenue | Major Customer Number Two          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage 24.00%   28.00%    
Customer Concentration Risk | Sales Revenue | Major Customer Number Three          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage 34.00%   27.00%